ArticlePediatric blood & cancer2018

Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.

Abhik Bandyopadhyay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.